文献速递慢阻肺

慢性阻塞性肺疾病疾病稳定性的定义:来自3期临床试验的证据

Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01

该研究对IMPACT、FULFIL、MATINEE/METREX/METREO试验进行事后分析,将COPD稳定性定义为无中/重度急性加重且CAT和FEV1较基线无恶化。FF/UMEC/VI组在IMPACT第52周有22%患者达到稳定,在FULFIL第24周有46%达到稳定;美泊利珠单抗联合三联治疗组在第52周有18%达到稳定。第28周达到稳定者后续中/重度急性加重风险降低45.7%,全因死亡风险降低51.7%。

要点

  • COPD稳定性可作为复合终点,定义为无中/重度急性加重且CAT和FEV1无恶化。
  • 第28周达到稳定预示后续急性加重和全因死亡风险显著降低。
  • 三联治疗和美泊利珠单抗联合三联治疗可提高达到稳定的概率。

核心结论

  • 疾病稳定性是COPD可实现的治疗目标,并能预测急性加重和死亡方面的长期临床获益。

研究设计与样本

  • 对IMPACT和FULFIL(FF/UMEC/VI vs 双联治疗)及MATINEE/METREX/METREO(美泊利珠单抗加三联治疗)进行事后分析。

主要发现

  • IMPACT中FF/UMEC/VI组第52周有22%患者达到稳定,FULFIL第24周有46%达到稳定。
  • MATINEE/METREX/METREO中美泊利珠单抗+三联治疗组第52周有18%患者达到稳定。
  • 第28周达到稳定者后续中/重度急性加重风险降低45.7%,全因死亡风险降低51.7%。
  • 贝叶斯联合模型显示FF/UMEC/VI第52周稳定的平均(SD)后验概率为25.60%(0.66)。

关键数值与推荐

  • 稳定性定义为无中/重度急性加重且CAT和FEV1较基线无恶化。

临床怎么用

  • 可将稳定性作为COPD治疗评估的复合目标,达到稳定提示长期预后改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Disease stability in chronic obstructive pulmonary disease (COPD) is a low disease activity state proposed as a treatment target. OBJECTIVES: Characterize COPD stability as a composite endpoint. METHODS: Post hoc analyses were carried out on IMPACT and FULFIL (fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI] vs dual therapies) and MATINEE/METREX/METREO (mepolizumab added onto triple therapy). Stability was defined as "no moderate/severe exacerbations and no worsening from baseline in COPD Assessment Test (CAT) and FEV1." We assessed whether achieving stability at week 28 was prognostic of subsequent outcomes (time to first on-treatment moderate/severe exacerbation and time to all-cause mortality [ACM]) after week 28 (IMPACT). Bayesian joint modeling evaluated the probability of achieving stability (IMPACT). MEASUREMENTS AND MAIN RESULTS: Stability was achieved with FF/UMEC/VI by 22% of patients in IMPACT (week 52) and by 46% of patients in FULFIL (week 24); stability was achieved with mepolizumab + triple therapy by 18% of patients in MATINEE/METREX/METREO (week 52). Patients were more likely to achieve stability with triple vs dual therapy and with mepolizumab vs placebo. Many individuals achieving stability had clinically meaningful improvements in CAT and FEV1. Patients achieving stability at week 28 (vs patients who were not stable) had a 45.7% reduction in the risk of moderate/severe exacerbations and a 51.7% reduction in the risk of ACM after week 28. Bayesian joint modeling demonstrated a mean (SD) posterior probability of stability: 25.60% (0.66) at week 52 (FF/UMEC/VI). CONCLUSIONS: Our data provide further evidence for disease stability as an achievable COPD treatment target that predicts long-term clinical benefits in exacerbations and mortality.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Singh, Stacey, Halpin, et al. Defining disease stability in chronic obstructive pulmonary disease: evidence from phase 3 clinical trials. Am J Respir Crit Care Med. 2026. PMID: 42281286. doi:10.1093/ajrccm/aamag292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。